The present invention is based on the discovery that the previously disclosed tetranuclear manganese compounds are converted into a hexadeca manganese aggregate and a core of 4 barium, 2 sodium and 1 chloride ion. Stated differently, one embodiment of the present invention comprises a composition of matter having the formula:
[Mn16 Ba8 Na2 ClO4 (OH)4 (CO3)4 (H2 O)22 l8 ]·xH2 O
wherein x is an integer ranging from 0 to about 32 and l is a ligand having the formula: ##STR1## Another embodiment of the present invention comprises a method of preparing the novel compounds of the present invention, which method comprises preparing an aqueous solution containing sodium chloride, a source of carbonate ion selected from sodium carbonate, sodium bicarbonate and mixtures thereof and a compound having the formula:
Ba2 [Mn4 (O)(OH)(O2 CR)2 l2 ]
wherein R is hydrogen or a hydrocarbyl group and l is a ligand having formula I set forth above, and thereafter allowing the reaction mixture to stand for a time sufficient for a compound having the formula:
[Mn16 Ba8 Na2 ClO4 (OH)4 (CO3)4 (H2 O)22 l8 ]·xH2 O
to form.
|
5. A hexadecanuclear manganese aggregate including a core of 4 barium ions, 2 sodium ions and 1 chloride ion and in which the core is surrounded by 16 manganese ions.
1. A composition of matter having the formula:
[Mn16 Ba8 Na2 C1O4 (OH)4 (CO3)4 (H2 O)22 l8 ].xH2 O wherein x is an integer ranging from 0 to about 32 and l is a ligand having the formula ##STR5## 6. A method for preparing a compound having the formula:
[Mn16 Ba8 Na2 C1O4 (OH)4 (CO3)4 (H2 O)22 l8 ].xH2 O wherein x is an integer of from 0 to about 32 and l is a ligand having the formula: ##STR6## comprising: forming an aqueous solution containing nacl, a source of CO3= and a compound having the formula: Ba2 [Mn4 (O) (OH) (O2 CR)2 l2 ] wherein R is hydrogen or a hydrocarbyl group and l is a ligand having the formula above; allowing the solution to stand for a time sufficient for the compound to form. 4. The composition of
7. The method of
8. The method of
9. The method of
11. The method of
|
|||||||||||||||||||||||||||||||||||||
This invention relates to novel compositions of matter and their method of preparation. More specifically, this invention relates to novel compounds including 16 manganese ions and a core of 4 barium, 2 sodium ions and a chloride ion.
In co-pending application Ser. No. 541,699, filed June 21, 1990, there is disclosed a composition of matter having the formula M2 [Mn4 (O)(OH)(O2 CR)2 L2 ]wherein M is an alkali earth metal selected from magnesium, calcium, strontium, barium or mixtures thereof, R is hydrogen or a hydrocarbyl group, and L is a ligand having the formula: ##STR2## These compounds have been shown to have a core structure of 4 manganese atoms which are bridged by oxo and hydroxo groups and, hence, they are referred to as oxo (hydroxo) bridged tetranuclear manganese compounds.
The present invention is based on the discovery that the previously disclosed tetranuclear manganese compounds are converted into a hexadeca manganese aggregate and a core of 4 barium, 2 sodium and 1 chloride ion. Stated differently, one embodiment of the present invention comprises a composition of matter having the formula:
[Mn16 Ba8 Na2 ClO4 (OH)4 (C03)4 (H2 O)22 L8 ].xH2 O
wherein x is an integer ranging from 0 to about 32 and L is a ligand having the formula: ##STR3##
Another embodiment of the present invention comprises a method of preparing the novel compounds of the present invention, which method comprises preparing an aqueous solution containing sodium chloride, a source of carbonate ion selected from sodium carbonate, sodium bicarbonate and mixtures thereof and a compound having the formula:
Ba2 [Mn4 (O)(OH)(O2 CR)2 L2 ]
wherein R is hydrogen or a hydrocarbyl group and L is a ligand having formula I set forth above, and thereafter allowing the reaction mixture to stand for a time sufficient for a compound having the formula:
[Mn16 Ba8 Na2 ClO4 (OH)4 (CO3)4 (H2 O)22 L8 ].xH2 O
to form.
The compounds of the present invention have magnetic properties rendering them particularly suitable for use in magnetic thermometry and magnetic fluids.
The accompanying figure is a perspective illustration of the structural arrangement of a novel compound of the present invention in which, for purposes of clarity, hydrogen atoms have been omitted; non-hydrogen atoms have been represented by arbitrary-sized spheres; the bonds between Mn and its coordinated atoms are represented by double lines; the bonds between Ba and its coordinated atoms are represented by dashed double lines; the bonds between Na and its coordinated atoms are represented by dashed solid lines; and the atoms labeled with additional indicia; e.g., ', *, '', +, &, and @, are related by symmetry.
The compounds of the present invention have the formula:
[Mn16 Ba8 Na2 C1O4 (OH)4 (CO3)4 (H2 O)22 L8 ].xH2 O
wherein x is an integer indicating the amount of water of crystallization, and as such, may vary over a broad range, for example, in the range of 0 to about 32, and L is a ligand having formula I set forth above. Preferably, x is an integer in the range of from about 16 to about 31.
As is shown in the figure, these novel compounds have a core structure of 4 barium and 2 sodium ions surrounding a chloride ion. These ions are referred to as main group elements. This main group element core is surrounded by 16 manganese ions.
The structure of the compounds of the present invention has been determined by well-known single crystal x-ray diffraction techniques.
The compounds of the present invention are prepared by combining an aqueous solution of sodium chloride, a source of carbonate ion such as sodium carbonate or sodium bicarbonate and a compound having the formula:
Ba2 [Mn4 (O)(OH)(O2 CR)2 L2 ]a
wherein R is hydrogen or a hydrocarbyl group, especially alkyl, aryl and aralkyl groups and, preferably, R is an alkyl group having from 1 to about 30 carbon atoms. More preferably, R has from 1 to about 10 carbon atoms, and when R is an aralkyl group, it preferably will have from 7 to about 10 carbon atoms. L is a ligand having the formula (I) shown previously.
The mole ratio of the tetranuclear manganese compound to sodium chloride used generally will be in the range of from about 1:0.25 to 1:25 and, preferably, in the range of from about 1:10 to about 1:15. The mole ratio of tetranuclear manganese compound to carbonate source (e.g., sodium hydrogen carbonate) used generally will be in the range of from about 1:1 to 1:100 and, preferably, from about 1:10 to about 1:20.
It should be readily appreciated that the tetranuclear compound can be prepared and used in situ and that it is not necessary to first prepare and isolate the tetranuclear compound.
The temperature at which the combined solution is maintained is not critical. Indeed, temperatures of from about 0°C to about 150°C may be used, but it is most convenient and preferred to combine the reactants in water at ambient room temperature, and maintain the mixture at that temperature.
The combined solution is then allowed to stand for a time sufficient for the formation of the desired compound. Typically, crystals of the compounds of the present invention form after the combined solution has been allowed to stand overnight. Alternatively, crystallization can be hastened by known techniques such as reducing the volume of solvent by evaporation, seeding the liquid phase and the like.
The crystalline hexadecanuclear manganese compound is readily separated from the aqueous solution by decantation or filtration. The value of x in the product compound, i.e., the amount of water of hydration, will, of course, depend on the extent of drying of the product. Consequently, x will vary broadly, for example, from about 0 to about 32.
The tetranuclear manganese complex used in preparing the novel compound of the present invention is prepared by combining an aqueous containing solution of the compound having the formula: ##STR4## with manganese (II) carboxylate Mn(O2 CR)2 or a water-soluble manganese (II) salt and a source of carboxylate RCO2-- in which R is hydrogen or a hydrocarbyl group and thereafter oxidizing the mixture to form the tetranuclear manganese compound. Exemplary hydrocarbyl groups for R include alkyl groups, aryl groups and aralkyl groups, and when R is an alkyl group, it will generally have from about 1 to 30 carbon atoms and, preferably, from 1 to 10 carbon atoms. When R is an aralkyl group, it will generally have from about 7 to about 10 carbon atoms.
Exemplary manganese (II) salts suitable for use in preparing the tetranuclear manganese compound include manganese chloride, manganese bromide, manganese nitrate, manganese tetrafluoroborate and manganese sulfate.
Exemplary sources of carboxylate include carboxylic acids and alkali metal salts of carboxylic acids.
Among suitable aqueous solutions are water, water-alcohol and water-dimethyl formamide mixtures. In general, it is particularly preferred to use water as the solvent in the preparation of the tetranuclear manganese complex.
The mole ratio of the barium compound (formula II above) to manganese (II) carboxylate or manganese (II) salt generally will be in the range of about 1:1 to about 1:3 and, preferably, about 1:2.
The hexadecanuclear manganese compounds of the present invention have a magnetic susceptibility above 100° K., which follows the Curie-Weiss law with θ=-7° K. This magnetic property renders the compounds of the present invention eminently suitable for use in magnetic thermometry and in magnetic fluids.
In the examples which follow, DHPTA refers to 1,3-diamino-2-hydroxypropane-N,N,N'N'-tetraacetic acid, the deprotonated form of which is shown previously as formula I.
In a 50 mL flask containing 5 mL of H2 O, 100 mgs of Ba(OH)2 were neutralized with concentrated HCl to pH7. Then 445 mgs of Mn(O2 CCH3)2.4H2 O were added, along with 10 mL of 1:1 H2 O/MeOH. In another 50 mL flask, 268 mgs of DHPTA were added to 10 mL of H2 O. This was neutralized with solid Ba(OH)2 while stirring. The two solutions were mixed together and stirred about 10 minutes, after which the pH was adjusted to 8.0 using Ba(OH)2 solid. Next, 1/2 mL of 30% H2 O2 was added dropwise. Then 5 mL of DMF were added. The mixture was stirred 10 minutes, filtered and the filtrate allowed to stand at ambient temperature while the product crystallized as the solvent evaporated. The solid tetranuclear manganese compound was separated by decanting the liquid and characterized by chemical and x-ray analysis.
PAC Preparation of the Mn16 Aggregate of This InventionTo 7 mL of an aqueous NaCl solution containing 50 mgs NaCl were added 100 mgs of Ba2 [Mn4 (O)(OH)(O2 CCH3)2 L2 ] prepared according to Example 1. After all the solids dissolved, 3 mLs of an aqueous solution containing 100 mgs NaHCO3 were added. Green crystals formed upon standing overnight. The crystals were separated by filtration and subjected to chemical analysis. The results of chemical analysis are:
Calculated for [Mn16 Ba8 O4 (OH)4 (H2 O)22 L8 ].16H2 O (Observed) % Cl: 0.63 (0.74); % C: 19.57 (19.67); % H: 3.18 (3.17); % N: 3.97 (3.94).
Additionally, the ratio of Ba to Mn was determined by inductively coupled plasma atomic emission spectroscopy (ICPE). The results are: Calculated (Observed): 1.25 (1.33). Finally, the product was subjected to x-ray analysis and the structure (see the figure) was determined using standard x-ray techniques.
PAC In Situ Preparation of the Mn16 AggregatesTo a 50 mL aqueous solution containing 268 mgs of DHPTA brought to a pH of 8 by addition of 10 mL of Ba(OH)2 solution were added 445 mgs of manganous acetate and 200 mgs of NaCl dissolved in a water/methanol mixture (volume ration 2:3). After stirring for 10 minutes, 0.5 mL of a 30% aqueous solution of H2 O2 were added slowly. Then 200 mgs of NaHCO3 were added to the mixture. A green crystalline solid formed on standing overnight. The crystalline solid was separated and was found by x-ray analysis to be the same as the product formed in Example 2.
PAC In Situ Preparation of the Mn16 AggregateThe procedure of Example 3 was repeated, except that 200 mgs of Na2 CO3 were added in lieu of the NaHCO3. The green crystalline solid was characterized by x-ray diffraction analysis to be consistent with the products prepared in Examples 2 and 3.
Gorun, Sergiu M., Stibrany, Robert T.
| Patent | Priority | Assignee | Title |
| 5922920, | Mar 10 1995 | Exxon Chemical Patents INC | Catalytic production of aryl alkyl hydroperoxides by polynuclear transition metal aggregates |
| 7966056, | Dec 16 2002 | Amersham Health AS | Magnetic resonance imaging method and compounds for use in the method |
| Patent | Priority | Assignee | Title |
| 4207245, | Jan 02 1979 | Exxon Research & Engineering Co. | Organometallic intercalates of metal chalcogenohalides |
| 4730064, | Mar 14 1985 | EXXON RESEARCH AND ENGINEERING COMPANY, A CORP OF DE | Heterometallic thiocubanes (C-2044) |
| 4937338, | Jun 05 1985 | BASF Aktiengesellschaft | Pigments |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Sep 10 1990 | Exxon Research and Engineering Company | (assignment on the face of the patent) | / |
| Date | Maintenance Fee Events |
| Dec 09 1994 | M183: Payment of Maintenance Fee, 4th Year, Large Entity. |
| Mar 16 1999 | REM: Maintenance Fee Reminder Mailed. |
| Aug 22 1999 | EXP: Patent Expired for Failure to Pay Maintenance Fees. |
| Date | Maintenance Schedule |
| Aug 20 1994 | 4 years fee payment window open |
| Feb 20 1995 | 6 months grace period start (w surcharge) |
| Aug 20 1995 | patent expiry (for year 4) |
| Aug 20 1997 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Aug 20 1998 | 8 years fee payment window open |
| Feb 20 1999 | 6 months grace period start (w surcharge) |
| Aug 20 1999 | patent expiry (for year 8) |
| Aug 20 2001 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Aug 20 2002 | 12 years fee payment window open |
| Feb 20 2003 | 6 months grace period start (w surcharge) |
| Aug 20 2003 | patent expiry (for year 12) |
| Aug 20 2005 | 2 years to revive unintentionally abandoned end. (for year 12) |